Decoy Therapeutics Inc Com Par 0.0001 New

Research Decoy Therapeutics Inc Com Par 0.0001 New (DCOY) on Bullrun: market cap USD 1.59M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.59M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0USD 12.52M-USD 5.40Mn/a-129.1USD 10.71MUSD 112.23KUSD 5.89M
FY2024n/aUSD 5.58M-USD 4.53Mn/a-69.54USD 2.43MUSD 221.87KUSD 1.51M
FY2023n/aUSD 12.54Mn/an/a-30.74USD 5.90Mn/aUSD 5.29M
FY2022USD 0-USD 31.61Mn/an/a-14.88USD 12.11Mn/aUSD 10.38M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.59Mn/an/an/a
20252025-12-31USD 4.14Mn/an/an/a
20242024-12-31USD 2.65Mn/an/an/a
20232023-12-29USD 2.53Mn/an/an/a
20222022-12-30USD 3.53Mn/an/an/a
20212021-12-31USD 23.21Mn/an/an/a

About Decoy Therapeutics Inc Com Par 0.0001 New

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Decoy Therapeutics Inc Com Par 0.0001 New's market cap?

Decoy Therapeutics Inc Com Par 0.0001 New's market capitalization is USD 1.59M.

What does Decoy Therapeutics Inc Com Par 0.0001 New do?

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs.